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The HDL hypothesis stating that simply raising HDL cholesterol (HDL-C) may produce
cardiovascular benefits has been questioned recently based on several randomized
clinical trials using CETP inhibitors or niacin to raise HDL-C levels. However, extensive
pre-clinical data support the vascular protective effects of administration of exogenous
ApoA-1 containing preβ-HDL like particles. Several small proof-of-concept clinical trials
using such HDL/ApoA-1 infusion therapy have shown encouraging results but definitive
proof of efficacy must await large scale clinical trials. In addition to HDL infusion therapy
an alternative way to exploit beneficial cardiovascular effects of HDL/ApoA-1 is to use
gene transfer. Preclinical studies have shown evidence of benefit using this approach;
however clinical validation is yet lacking. This review summarizes our current knowledge
of the aforementioned strategies.
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Epidemiology and HDL
Epidemiologic studies have, in general demonstrated an inverse relationship between the level
of HDL-C and the risk of atherosclerotic cardiovascular diseases (ACVD) (Miller and Miller,
1975; Gordon et al., 1977; Miller et al., 1977). If such a relationship were causal then it has been
estimated that for every 1 mg/dl increase in HDL-C level, there would have been a decrease of 2–
3% in coronary heart disease risk in men and women, respectively (Gordon et al., 1989). Given
the positive correlation between the level of LDL cholesterol (LDL-C) and ACVD risk and the
success of lowering LDL-C level pharmacologically or by other means to reduce ACVD events,
the medical community had embraced the idea that raising HDL-C level would similarly lead to
clinical benefit supporting the so called HDL hypothesis. This concept has been supported by the
demonstration that HDL and its ApoA-1 exhibit several biological actions that could favorably
affect athero-thrombosis. Furthermore, transgenic over-expression of ApoA-1 gene, direct infusion
of plasma derived or recombinant wild type or mutant ApoA-1 and gene transfer of other HDL
associated proteins have been shown to be athero-protective in various experimental and limited
clinical settings, thereby justifying current focus on HDL based therapies (Shah et al., 2001a,b).
Based on this notion, several clinical trials have been conducted to test the clinical efficacy of
HDL-C raising therapy. Cholesteryl ester transfer protein (CETP) inhibitors such as torcetrapib and
dalcetrapib are capable of raising HDL-C level by 72 and 30%, respectively. In the ILLUMINATE
trial, Torcetrapib plus Atorvastatin group experienced a significant excess in cardiovascular and
non-cardiovascular mortality despite a marked increase in HDL-C level and a significant additional
lowering of LDL-C level compared to recipients of Atorvastatin alone (Barter et al., 2007).
Similarly, torcetrapib plus atorvastatin did not affect the progression of atherosclerosis of carotid
or coronary arteries compared to Atorvastatin alone (Bots et al., 2007; Nicholls et al., 2008). In the
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dal-OUTCOMES trial, dalcetrapib, another CETP inhibitor
without known off target adverse effects failed to reduce the
risk of recurrent cardiovascular events in patients who had a
recent acute coronary syndrome (ACS) (Schwartz et al., 2012).
Currently there are two additional CETP inhibitors, Evacetrapib
(clinical trial identifier: NCT01687998) and Anacetrapib (clinical
trial identifier: NCT00685776), being tested in phase III
randomized clinical trials. These new CETP inhibitors produce
very large (>100%) increases in HDL-C as well as large
reductions in LDL-C (>20%) and the results of these trials will
provide further evidence in favor or against CETP inhibition.
However, the mechanism of any benefit, if found, may be difficult
to assign to HDL-C increase when there is a concomitant marked
reduction in LDL-C. Daily dose of niacin 1–3 gm raises HDL-C
level with concomitant lowering of plasma triglycerides, LDL-C
and possibly lipoprotein(a). The efficacy of niacin in reducing
ACVD events on top of effective statin therapy and LDL-C
lowering has been investigated in two clinical trials. In the AIM-
HIGH trial, treatment with extended-release niacin did not offer
incremental clinical benefit when given to patients on statin
therapy with baseline LDL-C level <70 mg/dl (Boden et al.,
2011). This trial was prematurely terminated because of futility.
In the HPS2-THRIVE trial, adding extended-release niacin in
combination with a flush inhibitor, laropiprant, to statin based
therapy did not confer clinical benefit in over and above statin
alone but instead increased the rate of adverse events (HPS2-
THRIVE Collaborative Group, 2013; Landray et al., 2014).
Fibrates are another class of agent that raise HDL-C and also
lower triglycerides. Fenofibrate was tested in the ACCORD study
in patients with type 2 diabetes on statin therapy and failed to
show reduction of AVCD events when compared to statin therapy
alone (Ginsberg et al., 2010). A full discussion of the pros and
cons of these clinical trials is beyond the focus of this review
and the reader is referred to several excellent reviews that have
addressed these issues (Kingwell et al., 2014; Tariq et al., 2014;
Tuteja and Rader, 2014).
These negative trials have challenged the HDL-C hypothesis
and many tangible reasons have been proposed to explain such
failures. These trials were conducted in patients on background
of effective statin treatment with well controlled LDL-C levels,
which could confound the efficacy of HDL-C raising therapy and
potentially the interpretation of the trial results. Torcetrapib was
shown to raise blood pressure through activation of the renin-
angiotensin-aldosterone pathway and such off target effect may
have contributed to its failure. It also remains unclear whether
the failure of niacin in HPS-2 study was related to the addition
of laropiprant, a PG DP1 receptor antagonist, to the niacin. It has
also been argued that failure of AIM-High trial may have reflected
a flaw in the trial design, i.e., underpowered to show a small
benefit. Experts in the field have also questioned if simply raising
the HDL-C level pharmacologically could translate to athero-
protective effects and have introduced the concept of quality or
the functionality of HDL and its protein components, especially
ApoA-1, in mediating the protective effect of HDL (Gadi
et al., 2013; Kypreos et al., 2013; Barylski et al., 2014; Karavia
et al., 2014). Others have re-examined the relationship between
HDL-C level and ACVD risk using Mendelian randomization
analysis. This analysis utilized screening the entire genome
for thousands of single nucleotide polymorphisms (SNPs) in
large cohorts to identify statistical relationships between clinical
outcomes and alleles associated with putative variables to
discover etiological factors in diseases (Kingwell et al., 2014).
Voight et al. reported that carriers of a SNP in endothelial lipase
gene (LIPG Asn396Ser) had higher HDL-C level but similar
levels of other lipid and non-lipid risk factors for myocardial
infarction compared with non-carriers. This difference in HDL-
C level was predicted to decrease risk of myocardial infarction
by 13% but in fact was not associated with such risk reduction.
Additionally a 1 SD increase in HDL-C level due to genetic
score was not associated with risk of myocardial infarction,
opposite to the observation from population epidemiology that
an increase of 1 SD in HDL-C level was associated with reduced
risk of myocardial infarction (Voight et al., 2012). Another study
using the same methodology also failed to find a causal effect
of HDL-C level on coronary heart disease risk (Holmes et al.,
2015). These genetic epidemiology studies further challenge the
concept of using HDL-C level as treatment target to test HDL-C
hypothesis.
Given the lack of support of HDL-C hypothesis by raising
HDL-C level pharmacologically, the quality and function of
HDL and its ApoA-1 becomes the current focus of intensive
research and potential future therapeutic targets. HDL is a
complex molecule that is heterogeneous in size and compositions
which may determine the functionality of the HDL particles
(Tsompanidi et al., 2010; Kypreos et al., 2013). Numerous
pre-clinical and clinical studies have reported diverse HDL
functions including reverse cholesterol transport, antioxidant,
anti-inflammatory properties, and immune-modulatory effect
(see below).
Mechanistic Basis for Beneficial Effects of
HDL and ApoA-1
Stimulation of Reverse Cholesterol Transport
One of the principle actions of ApoA-1 is to stimulate reverse
cholesterol transport to mobilize free cholesterol from the
peripheral tissues such as lipid laden macrophages and carry
the mobilized lipid to liver for uptake and elimination in feces
through biliary sterols. Free cholesterol and phospholipid from
the macrophage is transferred to lipid poor ApoA-1 discoid
particles by ABCA1 transporter and to larger spherical HDL
particles by ABCG1 transporter in the initial steps of the
reverse cholesterol transport; the free cholesterol is then esterified
by lecithin cholesterol acyl transferase leading to formation
of spherical HDL2 and HDL3 particles. HDL then delivers
cholesterol ester to the liver via SRB1 receptors or exchanges
cholesterol ester for triglycerides from VLDL and LDL particles,
an exchange facilitated by CETP. The cholesterol ester transferred
to LDL and VLDL is then targeted for hepatic uptake via the
LDL receptor pathway or accumulates in the arterial wall via
subendothelial retention. Thus, mobilization of free cholesterol
from arterial walls by ApoA-1 and HDL contributes to an anti-
atherogenic effect (Shah et al., 2001a).
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Anti-inflammatory and Immuno-modulatory
Effects
Inflammation and immune activation play an important role
in atherogenesis. Several reports have delineated the anti-
inflammatory properties of ApoA-1 in vitro. ApoA-1 inhibited
IL-1β and TNF-α production from T-cell activated monocytes
(Hyka et al., 2001). ApoA-1 also diminishes neutrophil
adhesion, oxidative burst and degranulation from activated
neutrophils; further implicating the ability of ApoA-1 to
modulate inflammation (Liao et al., 2005). Additionally ApoA-
1 affects dendritic cell maturation by rendering them less
responsive to anti-CD40 antibody and interferon-γ stimulation,
possibly via increased IL-10 and PGE2 production (Kim et al.,
2005). HDL may also promote migration of dendritic cells out
of vascular lesions into regional lymph nodes (Angeli et al.,
2004), possibly by neutralizing the dendritic cell immobilizing
effects of phospholipids generated during LDL oxidation. HDL
also attenuates the inhibitory effects of inflammation on reverse
cholesterol transport. Recent experimental observations have
shown that ABCA1 and ABCG1, critical players in the initial
steps of reverse cholesterol transport from macrophages and
critical regulators of HDL particle formation, play an important
role in suppressing atherosclerosis associated leukocytosis by
inhibiting bone-marrow derived progenitor cells (Yvan-Charvet
et al., 2010).
Anti-oxidant and Endothelial Protective Effects
HDL inhibits LDL oxidation, scavenges toxic phospholipids from
oxidized LDL and protects vascular smooth muscle cells and
endothelial cells from damaging effects of oxidized LDL. The
anti-oxidant effects of HDL have been attributed to Paraoxonase
(PON), Platelet Activating Factor Acetylhydrolase (PAF-AH)
carried by HDL (Shah et al., 2001a,b).
HDL protects endothelial cell functions by prevention
of oxidation of LDL and its adverse endothelial effects.
It also attenuates endothelial dysfunction from dyslipidemia
and atherosclerosis by SRB-1 dependent induction of eNOS,
attenuates endothelial cell apoptosis, and stimulates endothelial
reparative capacity (Kimura et al., 2006; Seetharam et al., 2006;
Mineo and Shaul, 2007; Pu and Liu, 2008). HDL from healthy
subjects can stimulate endothelial nitric oxide production during
endothelial repair processes (Besler et al., 2011) whereas HDL
from patients with atherosclerotic vascular diseases or type II
diabetes mellitus loses such function (Besler et al., 2011).
Antithrombotic Effects
HDL inhibits platelet aggregation, activates protein c and
inhibits assembly of the prothrombinase complex on anionic
phospholipid surfaces (Oslakovic et al., 2009). Native HDL
from human also significantly impaired OxLDL-induced platelet
aggregation and adhesion, decreased both the formation of
reactive oxygen species and CD40L expression (Badrnya et al.,
2013). Intravenous infusion with a reconstituted HDL (CSL-111)
in individuals with type II diabetes mellitus resulted in a >50%
reduction in the ex vivo platelet aggregation response, possibly
via reduction of the cholesterol content of platelet membranes
(Calkin et al., 2009). A recent report that elevated HDL-C levels
are associated with improved fibrin clot lysis also supports the
antithrombotic effects of HDL (Zabczyk et al., 2013).
Pancreatic Beta Cell Protective Effects and
Improving Glucose Intolerance
Insulin resistance and type II diabetes are often associated
with reduced levels of HDL-C. HDL infusion was shown
to improve pancreatic beta cell function in type 2 diabetic
patients. HDL may also protect against diabetes by reducing
stress induced pancreatic beta cell apoptosis. Furthermore,
ABCA1 and ABACG1 mediated anti-inflammatory effects of
HDL may attenuate islet cell inflammation that is implicated
in development of type 2 diabetes (Fryirs et al., 2009, 2010;
Kruit et al., 2010). ApoA-1, in lipid free form or complexed
with phospholipid, improved insulin sensitivity with decreased
systemic and hepatic inflammation in mice fed high-fat diet
(McGrath et al., 2014). ApoA-1Milano has similar effect as well
(Stenkula et al., 2014).
Pre-clinical and Clinical Studies of
HDL/ApoA-1/ApoA-1Milano Infusion
Intravenous Administration of Homologous HDL
The effects of in vivo administration of HDL on the development
of aortic fatty streaks were first tested in cholesterol-fed
rabbits. This tested the concept of using exogenous HDL as a
physiological acceptor for cholesterol from peripheral tissues.
Rabbits receiving weekly infusion of homologous HDL-VHDL
protein isolated from normal rabbit plasma developed smaller
fatty streak lesions in the aortic intimal surface with reduced
deposition of total and free cholesterol, esterified cholesterol,
and phospholipids in the vessel wall when compared to
control group receiving saline administration (Badimon et al.,
1989). The same investigators later reported that administering
exogenous HDL regressed the established fatty streak lesions in
cholesterol fed rabbits with reduced total cholesterol, esterified
cholesterol and phospholipids in aortic wall, suggesting increased
reverse cholesterol transport (Badimon et al., 1990). Interestingly
infusion of exogenous HDL did not alter circulating HDL-
C level (Badimon et al., 1990). Taken together, these findings
provided the initial support for the concept that the functionality
of HDL plays a more important role to reduce atherosclerosis
than the circulating level of HDL-C. Most plasma HDL-C exists
in spherical HDL2 and HDL3 with a smaller percentage of
HDL-C transported by small and discoidal particles with pre-β
electrophoretic mobility (preβ-HDL) (Conca and Franceschini,
2008). Lipid poor apolipoproteins, mainly ApoA-1, are the major
cholesterol acceptors for ABCA1 in the early steps of reverse
cholesterol transport pathway. Hence investigators have been
developing strategies to infuse purified ApoA-1 or synthetic HDL
made of a purified ApoA-1 (wild type or mutant) complexed with
a phospholipid.
Intravenous Infusion of ApoA-1Milano
ApoA-1Milano is a naturally occurring mutant of ApoA-1
(Arg173Cysteine) carried by a small number of inhabitants of
Limone sul Garda. The carriers are heterozygous for themutation
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and have an unexpectedly low prevalence of cardiovascular
disease and a family history of longevity despite very low HDL-C
and ApoA-1 levels (Sirtori et al., 2001).
Since the early 1990’s we have been investigating the vascular
protective effects of recombinant ApoA-1Milano complexed with
a phospholipid carrier in experimental models. We first reported
the striking athero-protective and anti-inflammatory effects
of intravenous infusion of r-ApoA-1Milano in cholesterol fed
rabbits undergoing balloon injury of their ileofemoral arteries
to accelerate lesion formation (Ameli et al., 1994). These results
were later replicated by Soma et al in a perivascular carotid
injury model in rabbits (Soma et al., 1995). Subsequently our
laboratory reported that frequent intravenous injections of r-
ApoA-1Milano would also halt progression of atherosclerosis in
ApoE−/− mice while reducing lipid and macrophage content
in lesions (Shah et al., 1998). In yet another study involving
ApoE−I mice, we demonstrated that a large single IV dose of r-
ApoA-1Milano would rapidly deplete lipid and macrophages from
atherosclerotic lesions within 48 h indicating the ability of this
intervention to rapidly mobilize tissue cholesterol (Shah et al.,
2001c). Similar findings were later reported by Chiesa et al in a
rabbit model of carotid plaque (Chiesa et al., 2002). Additional
work in our laboratory also demonstrated that r-ApoA-1Milano-
phospholipid complex could reverse endothelial dysfunction in
hypercholesterolemic apoE(−po) mice (Kaul et al., 2004) and
inhibit in-stent stenosis in porcine coronary arteries (Kaul et al.,
2003).
Such beneficial plaque stabilizing effect with short-term
treatment of ApoA-1Milano-phospholipids complex was
also demonstrated later by other investigators in a rabbit
atherosclerosis model with two infusions 4 days apart (Ibanez
et al., 2008) or five treatments every 4 days (Parolini et al.,
2008). The acute effect of short-term therapy with recombinant
ApoA-1Milano suggests the potential clinical application for acute
plaque stabilization in patients with ACS.
Based on the body of work described, rApoA-1Milano PC
complex was developed as a therapeutic intervention for clinical
testing by Esperion therapeutics (ETC 216). ETC-216 (Esperion
Therapeutics, Ann Arbor, Mich) was tested in a small proof of
concept clinical trial in which sequential intravascular ultrasound
studies done before and after 5 weekly infusions of ETC-216
or placebo. The study showed rapid coronary plaque regression
with rApoA-1Milano (Nissen et al., 2003). However, subsequent
clinical development was delayed by several years due to
manufacturing difficulties and contamination from host derived
proteins. Now a clean manufacturing process has been developed
to produce the rApoA-1Milano without contamination by host
derived proteins and this new material, called MDCO-216 (The
Medicines Company) has completed a phase 1 human trial
without problems and phase 2 trials are being planned for later
part of 2015 (Tardif, 2010).
A Canadian company, SemBioSys Genetics Inc, used a bio-
pharming technique to produce genetically modified saﬄower,
Carthamus tinctorius, that concentrates ApoA-1Milano in the oil
of their seeds (Nykiforuk et al., 2011). This plant engineered
ApoA-1Milano lacked first two amino acids (Des1,2 ApoA-1Milano)
compared to E. Coli derived rApoA-1Milano and appeared to
be functionally similar to E. Coli derived recombinant ApoA-
1Milano. Pre-clinical experiments in our laboratory using Des1,2
ApoA-1Milano have shown promising results (data presented
at Annual Scientific Sessions of the American College of
Cardiology in 2010 as an abstract; http://content.onlinejacc.org/
article.aspx?articleid=1141161). Unfortunately Des1,2 ApoA-
1Milano did not enter any clinical testing because SemBioSys
Genetics ceased operation in 2012 due to financial reasons and
bankruptcy.
Intravenous Infusion of Wild Type ApoA-1
Miyazaki et al. purified rabbit ApoA-1 from pooled plasma
of 500 rabbits and demonstrated intravenous infusion of such
purified homologous ApoA-1 was able to slow the progression
of atherosclerosis in cholesterol-fed rabbits (Miyazaki et al.,
1995).
The idea of infusing plasma derived human ApoA-1 into
humans was tested in the 1990s. Lipid free ApoA-1 infusion
into 6 men with low HDL-C level was able to increase plasma
total ApoA-1 concentration without eliciting adverse effects
and such increase was confined to the pre-beta region in the
plasma (Nanjee et al., 1996). The same group of investigators
subsequently showed infusion of ApoA-1-phosphatidylcholine
complex into healthymen increased the intravascular production
of small pre-β HDLs in vivo with associated increase in eﬄux
and esterification of unesterified cholesterol (Nanjee et al.,
1999). The small pre-β-HDL generated in plasma using this
approach was able to cross endothelium into tissue fluid and
promote eﬄux of unesterified cholesterol from peripheral cells
(Nanjee et al., 2001). Infusion of ApoA-1-phosphatidylcholine
complex into hypercholesterolemic patients rapidly normalized
endothelium dependent vasodilation as demonstrated by forearm
venous occlusion phethysmography (Spieker et al., 2002) but
such strategy failed to demonstrate similar vasodilatory benefit
in patients with ACS (Chenevard et al., 2012).
The efficacy of ApoA-1 infusion in patients with ACS was
further tested by infusing purified wild type ApoA-1 from
human plasma linked to soybean phosphatidylcholine (CSL-
111, CSL Behring) at 40mg/kg/infusion in the ERASE trial.
Five weekly infusions did not show a significant difference in
coronary atheroma volume in comparison to placebo (primary
end point); however when compared to pretreatment baseline,
CSL-111 recipients showed more regression in contrast to
the placebo arm (Tardif et al., 2007). The 80mg/kg/infusion
regimen was abandoned because of hepatic toxicity even though
in a separate study a single infusion of 80mg/kg favorably
reduced the expression of inflammatorymarker and lipid content
in the femoral artery plaque and raised HDL-C level and
cholesterol eﬄux capacity of apoB-depleted plasma (Shaw et al.,
2008).
CSL-112 is a successor of CSL-111 with an enhanced ability
to accept cholesterol from ABCA1 (Diditchenko et al., 2013).
When infused into human subjects, CSL-112 infusion was safe,
well tolerated and produced increases in ApoA-1 concentration
in a dose-dependent manner and remained elevated for 3 days
without evidence of major organ toxicity or immunogenicity
(Easton et al., 2014). In another study, infusion of CLS-112 into
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healthy human subjects increased HDL-C level and preferentially
ABCA-1 dependent cholesterol eﬄux capacity (Gille et al.,
2014). Based on these findings, CSL-112 will be tested in a
phase 2b randomized, placebo-controlled, dose-ranging trial
(ClinicalTrials.gov Identifier: NCT02108262) to investigate the
safety and tolerability of multiple dose administration of CSL-112
in patients with ACS with major adverse cardiovascular events as
its secondary end-point.
CER-001 is another engineered pre-β HDL mimic consisting
of recombinant human ApoA-1 and 2 different phospholipid
carriers. In pre-clinical study, CER-001 enhanced reverse
lipid transport, reduced vascular inflammation, and promoted
regression of atherosclerosis in hypercholesterolemic LDL
receptor deficient mice (Tardy et al., 2014). Despite these
beneficial effects in animal models, when tested in patients
with ACS, CER-001 failed to demonstrate any plaque-reducing
effect on coronary atherosclerosis as measured by IVUS and
QCA when compared with placebo in the randomized CHI-
SQUARE trial (Tardif et al., 2014). On the other hand,
CER-001 was able to stimulate cholesterol mobilization and
reduce artery wall dimension and inflammation in patients
with the orphan disease familial hypoalphalipoproteinemia
(Kootte et al., 2015). In another orphan disease, homozygous
familiar hypercholesterolemia, bi-weekly infusion of CER-
001 infusions significantly reduced carotid mean vessel wall
area and mean vessel volume at 6 months as assessed
by carotid MRI in the MODE (Modifying Orphan Disease
Evaluation) study (http://www.eas-society.org/news-from-late-
breaking-session-2.aspx, EAS 2014).
Intravenous Re-infusion of Endogenous
Delipidated HDL
Based on the hypothesis that lipid poor ApoA-1 particles
are particularly effective in stimulating ABCA1 mediated
reverse cholesterol transport, the idea of re-infusing ex vivo
delipidated endogenous plasma HDL was tested in a small
human trial (LS-001, Lipid Sciences Selective Delipidation
Trial). Eligible patients with ACS scheduled for cardiac
catheterization with a nonobstructive atheroma in ≥1 native
coronary arteries were randomized to HDL delipidation
or control, and subjected to apheresis/reinfusion for seven
sessions each, 1 week apart. IVUS evaluation of the target
vessel showed a non-statistically significant coronary plaque
regression as measured in patients receiving re-infusion of
autologous plasma containing delipidated HDL (Waksman et al.,
2010).
Summary
Some, but not all, experimental studies have suggested that
ApoA-1Milano has more potent athero-protective effects than wild
type ApoA-1 (Wang et al., 2006; Lebherz et al., 2007; Feng et al.,
2009; Ibanez et al., 2012). Overall, the strategy of short term
infusion of synthetic HDL (containing ApoA-1Milano or wild
type ApoA-1) is a promising pharmacological approach for rapid
plaque remodeling and stabilization. Table 1 summarizes the
results from currently available clinical studies using this strategy
that could later be sustained with the use of orally effective LDL
lowering and possibly HDL function improving agents or even
possibly repeated infusions.
TABLE 1 | Clinical studies using HDL/ApoA-I infusion as therapeutic agent.
Formulation Name of agent Tested patient population Primary outcome
Recombinant ApoA-IMilano/phospholipid
complex
ETC-216 Acute coronary syndrome Coronary atherosclerotic plaque regression in the
treatment group
Purified wild type ApoA-I from human
plasma complexed with
phosphatidylcholine
CSL-111 Acute coronary syndrome Coronary atherosclerotic plaque regression in the
treatment group
CSL-111 Patients with claudication scheduled for
percutaneous revascularization
Reduction of VCAM-1 expression and lipid content in the
plaque; increase in HDL-C level and capacity of
cholesterol efflux
Purified wild type ApoA-I from human
plasma complexed with
phosphatidylcholine
CSL-112 Healthy subjects Dose-dependent increase in ApoA-I concentration
without organ toxicity or immunogenicity
CSL-112 Healthy subjects Increase in ABCA-I dependent cholesterol efflux
CSL-112 Acute coronary syndrome Ongoing phase 2b trial to evaluate hepatic and renal
safety and tolerability of CSL112
Recombinant human ApoA-I complexed
with phospholipid
CER-001 Acute coronary syndrome No change on coronary atherosclerotic plaque volume
CER-001 Familial hypoalpha-lipoproteinemia Stimulation of cholesterol mobilization and reduction of
artery wall dimension and inflammation
CER-001 Homozygous familiar hypercholesterolemia Reduction of carotid mean vessel wall area and volume
Delipidated autologous plasma HDL LS-001 Acute coronary syndrome Non-significant regression of coronary atherosclerosis
plaques in the treatment group
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ApoA-1 and ApoA-1Milano Gene Therapy
Although intravenous infusion of synthetic ApoA-1 (wild type
or Milano mutant) is potentially safe for clinical application,
it is limited for clinical use due to the high cost of large
scale production of ApoA-1 and need for repeated intravenous
administration. Therefore, gene therapy could be an alternative
approach to exploit athero-protective effects of ApoA-1 or ApoA-
1Milano for its possible long-term effect. We have previously
shown that transplantation of bone marrow transduced with
a retroviral vector containing a macrophage specific promoter
and ApoA-1Milano gene significantly reduces atherosclerosis and
plaque inflammation in hyperlipidemic mice despite low levels of
circulating levels of transgene (Wang et al., 2006). In this study we
also demonstrated substantially superior athero-protective effects
of ApoA-1Milano gene transfer compared to wild type ApoA-1
gene transfer supporting the possible gain of function nature
of the Milano mutation. We have recently shown that a single
intravenous injection of AAV8 encoding ApoA-1Milano gene
produces significant inhibition of atherosclerosis progression in
hyperlipidemic mice (Tian et al., 2015). Furthermore, using a
model of established advanced atherosclerosis in mice, we have
also shown that the combination of low fat diet and AAV8
mediated ApoA-1Milano gene transfer produces robust regression
of atherosclerosis in genetically engineered mice (In Press:
Journal of Clinical Pharmacology and Therapeutics). Several
other pre-clinical studies have also demonstrated that effective
transfer of genes encoding ApoA-1 or ApoA-1 mutants using
viral vectors produce significant reduction and or promote
regression of atherosclerosis (Pászty et al., 1994; Tangirala et al.,
1999; Ishiguro et al., 2001; Major et al., 2001; Su et al., 2003),
however clinical translation of such studies has not been reported
to date.
For clinical application of gene therapy for atherosclerosis to
become a reality, such strategy needs to overcome the following
challenges—these have largely to do with the development of
high efficiency, safe, non-immunogenic, scalable vectors that can
lead to stable and long term transgene expression in the host
without provoking adverse immunologic or non-immunologic
complications. Recent progress in recombinant AAV technology
is encouraging in this regard (Asokan and Samulski, 2013;
Dismuke et al., 2013; High et al., 2014; Kotterman and Schaffer,
2014).
Perspectives
In this review, we have discussed many approaches to exploit the
well-established vascular protective effects of HDL and its major
protein ApoA-1 with promising results in both pre-clinical and
limited clinical studies. Once proven effective and safe in humans,
they will be valuable additions to our current pharmacological
armamentarium to treat atherosclerotic cardiovascular disease
and its associated complications. The HDL-C hypothesis needs
to be reinvented into the HDL hypothesis with emphasis on
composition and functionality of HDL particles rather than
HDL-C levels.
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